CagriSema versus semaglutide for weight loss in obesity, with or without type 2 diabetes
Compares CagriSema with semaglutide for weight loss in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Key facts
- Where
- Buenos Aires, CABA, Capital Federal, Ciudad Autónoma de Buenos Aires, Ciudad de Buenos Aires, San Miguel de Tucumán, Santa Fe, and Santiago del Estero, ArgentinaSee the 15 sites
- Phase
- Phase 3
Where in Argentina
- Centro Medico Dra. Laura Maffei e Investigacion Clínica ApliBuenos Aires, ArgentinaNo longer taking part
- Hospital Sirio LibanesBuenos Aires, ArgentinaNo longer taking part
- Kynet RecoletaBuenos Aires, ArgentinaNo longer taking part
- OMI- Organización Médica de InvestigaciónBuenos Aires, ArgentinaNo longer taking part
- Cedic - Centro de Investigacion ClinicaCABA, ArgentinaNot yet recruiting
- CEMEDICCABA, ArgentinaNo longer taking part
- Centro Médico Viamonte SRLCABA, ArgentinaNo longer taking part
- CIPREC ArenalesCABA, ArgentinaNo longer taking part
- Centro de Investigaciones MetabólicasCapital Federal, ArgentinaNo longer taking part
- Centro Médico ArsemaCiudad Autónoma de Buenos Aires, ArgentinaNo longer taking part
- CICEMO- Consultorio (Av Directorio)Ciudad Autónoma de Buenos Aires, ArgentinaNo longer taking part
- Instituto CentenarioCiudad de Buenos Aires, ArgentinaNo longer taking part
- Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de JulioSan Miguel de Tucumán, ArgentinaNo longer taking part
- CEDIR - Centro de diagnóstico y rehabilitación Santa FeSanta Fe, ArgentinaNo longer taking part
- Sanatorio NorteSantiago del Estero, ArgentinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07564414EU 2025-522488-14-00
- Record updated
- 30 September 2026
- Original description
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeksRead full original descriptionShow less
A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent; BMI≥ 35.0 kg/m\^2; Participants without T2D: No history of T2D and HbA1c < 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.
Exclusion: A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records; Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.